Upload
88akk
View
234
Download
0
Embed Size (px)
Citation preview
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
1/31
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
2/31
Introduction
Historical overview Definition of ADR
Classification of ADR
Pharmacokinetic variations
Pharmacodynamic variations
Genetic variability in drug metabolizing enzymes
Genetic variability in drug transporters
Immunogenetic & Receptor polymorphism Miscellaneous drug targets
Conclusion
References
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
3/31
Adverse drug reactions (ADRs) representa major public health problem
6.7%of hospitalized patients developsevere ADRs
In children the overall incidence of ADRs
is as high as 9.5% The overall cost of drug related morbidity
and mortality in US has been estimatedto be more than 76billion$
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
4/31
4% of drugs marketed in UK over a 20year period were withdrawn because ofsafety issues
Many factors contribute to the
occurrence of ADRs. those are-Environmental factors
- Genetic factors
Significant proportions of ADRs mayoccur because of geneticpredisposition(genetic factors.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
5/31
Certain enzymes metabolise 5 to 25% ofall prescribed drugs respectively but inADRs they metabolize 38 to 75% of drugs
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
6/31
PYTHAGORAS in 510bc,southern Italyreported that ingestion of fava beans canlead to red cell hemolysis in some
individuals but not all The same was observed with Primaquine
administration in 1956 because of G6PDdeficiency.
Another classical example reported in 1950was the occurrence of prolonged apnoeaafter treatment with Suxamethonium in ptswith deficiency of butyrylcholinesterase.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
7/31
The first ADRs with a P450 polymorphism wasthe occurrence of hypotension withDebrisoquine led to discovery of CYP2D6.
Genes other than those coding forproteins involved in drug disposition mayalso predispose to ADRs.
HLA has been a focus of interest for manyyears, eg: Hydralazine induced lupus inpatients who are HLA-DR4 positive.
Individuals who are slow acetylators andHLADR4 positive have a higher risk thanthose with one risk factor only.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
8/31
A noxious change which is suspected to
be due to a drug, occurs at dosesnormally used in man, requires treatmentor decrease in dose of indicates cautionin the future use of the same drug.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
9/31
Results in death
Life threatening
Hospital admissions
Disability&Incapacity
Congenital anomaly or birth defect
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
10/31
Type A:Augmented
Type B:Bizarre reaction
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
11/31
ADRs can occur as an result of variability
of either the pharmacokinetic orpharmacodynamic properties of thedrug.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
12/31
Geneticfactors
P.kinetic
P.dynamic
ADRs
Environmental factors
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
13/31
Gene symbol title drug ADR
BCHE,CHE1 Butyrylcholineesterase
SCH Prolongedapnoea
CYP2C9 Cytp450 2c9 Warfarin Bleeding
CYP1A2 Cyt450 1a2 Phenacetin hypersensitivity
CYP2D6 Cytp4502d6 Codeine Increasedrespiratorypsychomotorand pupillaryeffects
GSTM1&GSTT1 Glutathione stransferase Tacrine transaminitis
GSTM1 glutathione stransferase
Cisplatin ototoxicity
GSTM1&GSTT1 Glutathione s
transferase
Troglitazone hepatotoxicity
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
14/31
Gene symbol Name Drug ADR
HERG Voltage gatedK+
channels
ErythromycinCisapride
ClarithromycinLQTS
Torsa de pointes
RYR1 Ryanodinereceptor
Halothane Malignanthyperthermia
OPRM1 Mu Opioidreceptor
Morphine Addiction
G6PDG6P
dehydrogenase Primaquine
Sulfonamides
Hemolytic
anemia
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
15/31
Eg:
1.association of CYP2C9 polymorphism
with Warfarin dose requirement and therisk of bleeding.
2.slow acetylation has been associated
with number of adverse effects. Sulfasalazinevomiting.
Isoniazidneuropathy.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
16/31
Eg: phenacetin, an analgesicwithdrawn from UK because of its
potential to cause-Nephrotoxicity
-Carcinogenicity
-Methhemoglobinemia.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
17/31
This is liable to be important when the drugitself is inactive but has an active metabolite
responsible for its pharmacological andtoxicological activities.
codeine CYP2D6 morphine
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
18/31
Idiosyncratic drug toxicity is thought to becaused not by the parent drug but by its
toxic metabolite by a process termedBIOACTIVATION.
Such toxic metabolites can be readilydetoxified in the majority of individuals by aprocess called BIOINACTIVATION.
Eg: sulfamethoxazole cyp2c9 hydroxylamine
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
19/31
Bioinactivation of toxic metabolites can benon enzymatic and enzymatic(glutathiones transferase).
Eg:
Cisplatinototoxicity
Tacrinetransaminitis
Troglitazonehepatotoxicity
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
20/31
Transport proteins that actively mediatethe influx and efflux of drugs across cell
membranes have an important role inregulating the absorption distributionand excretion of many medicines.
Polymorphisms have been described in
many of the genes encoding for theseproteins.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
21/31
Efflux pump may mediate toxicity via thefollowing possible pathways-
Reduced activity of efflux pump
Reduced renal and biliary excretion
Increased oral bioavailability
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
22/31
Reduced activity at the level of cell membrane
Increased intracellular levels
Increased toxicity of drugs
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
23/31
ADRs associated with polymorphism inMDR1 gene.
Eg:-Tacrolimus- Neurotoxicity
-Cyclosporine- Cyclosporine toxicity
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
24/31
Ex:1 Use ofAbacavirProduces hypersensitivityreaction , HLA associated are B-5701,DR-7,DQ-3.
2.CBZ produces Steven-johnson syndrome
and toxic epidermal necrolysis, associated withhaplotype TNF2-DR3-DQ2.
3.Clozapine induced agranulocytosisassociated with HLA haplotypes DRB1-0402,0302and DQA1-0301.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
25/31
Ex: 1.Clozapine induced weight gain associatedwith genes encoding 5-HT2C,3.
2.Clozapine induced tardive dyskinesia
associated with genes encoding dopaminergicreceptors.
3.Halothane induced malignanthyperthermia is due to mutation in ryanodinereceptor gene.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
26/31
Drug induced long QT interval (LQT):
Mutations in genes coding for cardiac
K+
and Na+
channels may cause LQTS. Oral contraceptive induced venous
thrombo embolism :
Mutations in coagulation factor V andprothrombin genes are known to be riskfactors for venous thromboembolism.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
27/31
Methotrexate induced toxicity:
Genetic variability in methylenetetrahydrofolate reductase(MTHFR)has been found to be associated withhigher riskof developing adversereactions with MTX.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
28/31
ACE inhibitor induced cough:
Polymorphism in ACE and bradykinin B2receptor genes.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
29/31
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
30/31
Aithal, G.P., Day, C.P., Kesteven, P.J., and Daly, A.K.Association of polymorphisms in the cytochrome P450 CYP2C9with warfarin dose requirement and risk of bleedingcomplications. Lancet,1999,353:717-719.
Alving, A.S., Carson, P.E., Flanagan, C.L., and Ickes, C.E.Enzymatic deficiency in primaquine-sensitive erythrocytes.Science,1956,124:484-485.
Arranz, M.J., Munro, J., Birkett, J., et al. Pharmacogeneticprediction of clozapine response [letter].Lancet,2000,355:1615-1616.
Ana Alfirevic, B.kevin park,Pharmacogenetics of ADRs,Clinicalpractice and Pharmacogenetics.
Goodman &Gilmans,Pharmacological basis oftherapeutics,11th edition.
7/28/2019 Pharmacogenetics of Adverse Drug Reactions
31/31